title: [Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].
abstract: Immunotherapy for treatment of solid cancer mostly is an experimental treatment. In contrast, intravesical immunotherapy of superficial bladder cancer with bacille Calmette-Guérin (BCG) is clinically well established and accepted worldwide because of better results compared to topical chemotherapy. BCG is currently regarded as the most successful immunotherapy of cancer. Unfortunately the mechanism of action has not yet been fully clarified. This article gives an overview on the complex research on the mechanisms of actionhighly successful therapy.
authors.affiliation: Urologische Abteilung, HELIOS Agnes-Karll-Krankenhaus, Am Hochkamp 21, 23611, Bad Schwartau. boehle@urologie-bad-schwartau.de
authors.forename: A
authors.initials: A
authors.lastname: Böhle
authors.forename: H
authors.initials: H
authors.lastname: Suttmann
authors.forename: S
authors.initials: S
authors.lastname: Brandau
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000008:administration & dosage*; D019496:Cancer Vaccines / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems / Q000379:methods*; D015195:Drug Design; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001500:BCG Vaccine; D019496:Cancer Vaccines